The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:36 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #28. Agenus Inc. 4-Antibody AG

Acquirer: Agenus Inc. (NASDAQ:AGEN)
Acquiree: 4-Antibody AG
Details: Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that it has entered into a definitive agreement to acquire 4-Antibody AG, a private European-based biopharmaceutical company. 4-Antibody has a technology platform for the rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets of interest. These targets include checkpoint molecules that regulate immune response to cancers and other diseases. The company has multiple preclinical immune checkpoint antibody programs targeting numerous checkpoint molecules, including GITR and OX40, as well as four additional undisclosed checkpoint programs. These checkpoint programs are being pursued through a strategic collaboration with the Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center (MSKCC) in New York.

Agenus is a clinical-stage immuno-oncology company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in trials of balstilimab monotherapy and balstilimab/zalifrelimab combination for patients with second-line cervical cancer. Co. is also developing its proprietary anti-CTLA-4 antibody, AGEN1181, which is designed to expand the population of patients benefiting from anti-CTLA-4 therapy. Co.'s AgenTus Therapeutics, Inc. subsidiary focuses on allogeneic cell therapies.

AGEN SEC Filing Email Alerts Service

Open the AGEN Page at The Online Investor »

Company Name: 
Agenus Inc
Number of ETFs Holding AGEN: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the AGEN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
99th percentile
(ranked higher than approx. 99% of all stocks covered)

Analysts' Target Price:
AGEN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 28 of 83 Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.